After receiving several positive feedback from European and US health agencies, Hemerion is preparing to scale up its teams for the implementation of a pivotal clinical trial, the last step before the market authorization of its flagship therapy Pentalafen / Heliance.
To structure the implementation of the pivotal clinical trial giving access to the American and European markets, Hemerion is evolving two members of its team to key positions.
Sacha Coquelle is appointed Product Line Manager and takes full responsibility for the development and industrialization of the Heliance® illumination platform. His mission covers the entire value chain, from design to supply chain management, to ensure rapid deployment in the context of the next trial and the ramp-up for launch on the American and European markets.
In the same vein, Antoine Méquignon is named Director of Clinical Operations to structure, set up, and steer the pivotal clinical trial, with the objective of a green light from health authorities around 2029.